Abstract
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
Full Text
Sign-in/Register to access full text options
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have